Omalizumab and Mast Cell Disorders: Are We There Yet?

Affiliations

Editorial

Catherine R Weiler. J Allergy Clin Immunol Pract. 2019 Sep-Oct.

. 2019 Sep-Oct;7(7):2396-2397.

doi: 10.1016/j.jaip.2019.04.030.

¹ Division of Allergy, Mayo Clinic, Rochester, Minn. Electronic address: Weiler.catherine@mayo.edu.

No abstract available

Comment on

Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS.
Lemal R, Fouquet G, Terriou L, Vaes M, Livideanu CB, Frenzel L, Barete S, Canioni D, Lhermitte L, Rossignol J, Arock M, Dubreuil P, Lortholary O, Hermine O. Lemal R, et al. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2387-2395.e3. doi: 10.1016/j.jaip.2019.03.039. Epub 2019 Apr 5. J Allergy Clin Immunol Pract. 2019. PMID: 30954641 Clinical Trial.